UCB (EBR:UCB) UCB Media Room: Share Repurchase Program 2021
Transparency directive : regulatory news
05/03/2021 20:08
https://mb.cision.com/Public/18595/3301187/a2c6b78674ae205f_800x800ar.jpg
** Share Repurchase Program 2021 to cover UCB's Long Term Incentive Plans f=
or its employees
------------------------------------------------------------
Brussels (Belgium), 5 March 2021 =E2=80=93 20:05 (CET) =E2=80=93 regulated =
information
In application of article 7:215 of the Belgian Code of Companies and Associ=
ations, UCB SA/NV (=E2=80=9CUCB=E2=80=9D or the =E2=80=9CCompany) (Euronext=
Brussels: UCB) announces the launch of a share buy-back program (the =E2=
=80=9CShare Repurchase Program 2021=E2=80=9D), effective as of 8 March 2021=
.=C2=A0
The repurchase of UCB shares under this program intends to cover current an=
d future obligations under UCB's Long Term Incentive Plans for its employee=
s. UCB will continuously monitor both its current and future obligations un=
der such plans in view of keeping an adequate level of treasury shares.
Under this program, UCB may acquire from time to time its common stock, for=
a maximum of 750 000 shares. The share repurchases will be conducted under=
the terms and conditions approved by the extraordinary general shareholder=
s=E2=80=99 meeting of the Company held on 30 April 2020. The timing of the =
repurchase of shares pursuant to the program will depend on a variety of fa=
ctors, including market conditions. The program may be suspended or discont=
inued at any time.
UCB has requested a financial intermediary to repurchase UCB shares on its =
behalf under the terms of an initial discretionary mandate agreement with v=
alidity until 25 June 2021.=C2=A0
During the Share Repurchase Program 2021, regular updates will be published=
in accordance with applicable legislation.
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://www.ucb.com/stories-media/Press-Releases) .
Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com
Isabelle Ghellynck,
=C2=A0Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 400 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Fol=
low us on Twitter: @UCB_news
GenericFile
20210305 - UCB Programme de rachat d actions propres 2021 FR (https://mb.ci=
sion.com/Public/18595/3301187/a8bb17dbe848a272.pdf) GenericFile
20210305 UCB Share Repurchase Program 2021 ENG (https://mb.cision.com/Publi=
c/18595/3301187/b592b9b71ecbc643.pdf) GenericFile
20210305 UCB Aandelen Inkoop Programma 2021 NED (https://mb.cision.com/Publ=
ic/18595/3301187/b31b6497ca7efd24.pdf)=0D
=0D
______________________=0D
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x63194x1x6868579x24000=
x6&Email=3Dregnews%40symexglobal.com.=0D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=